Evaluation of cross-platform compatibility of a DNA methylation-based glucocorticoid response biomarker
Abstract
Identifying blood-based DNA methylation patterns is a minimally invasive way to detect biomarkers in predicting age, characteristics of certain diseases and conditions, as well as responses to immunotherapies. As microarray platforms continue to evolve and increase the scope of CpGs measured, new discoveries based on the most recent platform version and how they compare to available data from the previous versions of the platform are unknown. The neutrophil dexamethasone methylation index (NDMI 850) is a blood-based DNA methylation biomarker built on the Illumina MethylationEPIC (850K) array that measures epigenetic responses to dexamethasone (DEX), a synthetic glucocorticoid often administered for inflammation. Here, we compare the NDMI 850 to one we built using data from the Illumina Methylation 450K (NDMI 450).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 28, 2022
- Source ID
- 10.1186/s13148-022-01352-1
Entities
People
- Annette M Molinaro
- Brock C Christensen
- Devin C Koestler
- Emily Tang
- Gayathri Warrier
- Helen M. Hansen
- Jennie W. Taylor
- Jennifer L. Clarke
- John K Wiencke
- Karl T. Kelsey
- Lucas A. Salas
- Lucie Mccoy
- Margaret Wrensch
- Paige M. Bracci
- Terri Rice
Organizations
- Congressionally Directed Medical Research Programs
- National Brain Tumor Society
- National Institute of General Medical Sciences
- National Institutes of Health